meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Inclusion Criteria: * Signed and dated written informed consent. * Patients aged ≥18 years on PD with RKF defined as at least 250 cc of urine output per day (assessed via 24-hour urine collection) and a minimum measured GFR of 2 ml/min/1.73m2, as measured at least once in the last 3 months. * Stable PD prescription, as determined by investigators. * Stable dose of RAAS blockade if on a medication within this class for the last 30 days. Exclusion Criteria: * Type 1 diabetes. * Recent (in the 30 days prior to screening) acute coronary syndrome or cerebrovascular event. * PD peritonitis within 30 days of screening. * History of organ transplant, including pancreas, pancreatic islet cells or kidney transplant. * Planned surgery/procedures or radiologic investigations requiring contrast during the trial. * Pregnant, planning to become pregnant, or nursing an infant during the study period * History of any DKA event * Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, hemolytic anemia) at screening. * Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial. * Alcohol or drug abuse within the 3 months prior to screening that would interfere with trial participation based on Investigator's judgement. * Use of SGLT2 inhibitor within 30 days prior to screening. * Intake of an investigational drug in another trial within 30 days prior to screening. * Patient not able to understand and comply with stu…